Systemic Oral Enzymes in Cancer Therapy
the U.S. Food and Drug Administration has approved investigational new drug status for use of a systemic oral enzyme preparation (i.e., Wobe-Mugos® from Mucos Pharma GmbH) in treatment of Multiple Myeloma. It was found that treatment with Wobe-Mugos® in addition to conventional chemotherapy prolongs remission times in stage II multiple myeloma patients and reduces the concentrations of progression markers.
WOBE-MUGOS is not available in US but Wobenzyme N has the same ingredients – Chymotrypsin and papain might be the active ingredients. But Wobenzyme N is half as concentrated – so they think that you can take twice as much of this as the Wobe-MUGOS.
These benefit overall immunity and help reduce the side effects of chemo and radiation.
- Wobenzyme N seems to inhibit Metastasis (spread of cancer).
- Multiple Myeloma (prolongs remission)
- Stomach cancer (5400 patients increased survival rate in more than 505 of patients)
- Colon cancer (patients survived longer)
- Pancreatic cancer (substantial reduction in pain and one to two years longer survival)
- Gynecological cancers all seem to have better outcomes
Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
256 patients with MM in 2 groups half with chemo and half with chemo plus oral enzymes for 6 months.
Control group Stage 1 followup 33 mo, stage 2 follow up 37 mo, Stage 3 follow up 31.5 mo
chemo plus Oral Enzymes stage 1 follow up 61 months, stage 2 follow up 51.5 mo, stage 3 follow up 46.5 months
Significantly higher overall response rates and longer duration of remissions were observed in the group that added oral enzymes. It decreased the hazard of death for patients at all stages of disease by about 60%!! Stage 1 & 11 were still alive, but Stage 3 survived 83 months when oral enzymes were added compared to 47 months in the control group.